{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:57:58Z","timestamp":1793059078647,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clindermatol.2026.07.030","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:22:49Z","timestamp":1786033369000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating glucagon-like peptide-1 receptor agonists into dermatology practice: Safety and monitoring strategies"],"prefix":"10.1016","author":[{"given":"Shanthi","family":"Narla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika R.","family":"Narla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.07.030_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0002","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jama.2025.14392","article-title":"New molecules and indications for GLP-1 medicines","volume":"334","author":"Gonzalez-Rellan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0003","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/oby.23521","article-title":"Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy","volume":"30","author":"Malik","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obesity Pillars"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0005","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/medicina61111987","article-title":"Gastrointestinal adverse effects of anti-obesity medications in non-diabetic adults: a systematic review","volume":"61","author":"Takrori","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036730","article-title":"Semaglutide-associated hyposalivation: a report of case series","volume":"102","author":"Mawardi","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0007","unstructured":"ADANews. Ozempic may yield weight loss but also bad breath."},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114793","article-title":"GLP-1 receptor agonists significantly impair taste function","volume":"291","author":"Khan","year":"2025","journal-title":"Physiol Behav"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoto.2026.1498","article-title":"Smell and taste disturbances among glucagon-like peptide-1 receptor agonist users","author":"Zontag","year":"2026","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","article-title":"GLP-1 agonists: a review for emergency clinicians","volume":"78","author":"Long","year":"2024","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13300-021-01198-5","article-title":"Glucagon-Like peptide-1 receptor agonist use in people living with type 2 diabetes mellitus and chronic kidney disease: a narrative review of the key evidence with practical considerations","volume":"13","author":"G\u00f3rriz","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0012","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0013","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study","volume":"15","author":"Scott Butsch","year":"2025","journal-title":"Obes Pillars"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2025.1566498","article-title":"Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study","volume":"12","author":"Johnson","year":"2025","journal-title":"Front Nutr"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0015","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1111\/dom.16368","article-title":"The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus-A pilot study","volume":"27","author":"Melis","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0016","doi-asserted-by":"crossref","first-page":"907","DOI":"10.15537\/smj.2025.46.8.20240100","article-title":"GLP-1 analog therapy and hemoglobin levels: insights from a retrospective study","volume":"46","author":"Almuammar","year":"2025","journal-title":"Saudi Med J"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0017","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0018","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0019","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff A\uff0e","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0022","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding J\uff0e","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0023","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0024","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","article-title":"Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: a systematic review and meta-analysis","volume":"82","author":"Ebrahimi","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.07.001","article-title":"GLP-1 agonists and risk of suicidal thoughts and behaviours: confound by indication once again? A narrative review","volume":"87","author":"Strumila","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0027","article-title":"Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA adverse event reporting system database","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0028","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamapsychiatry.2026.1716","article-title":"Use and misuse of glp-1 receptor agonists among people with eating disorders","volume":"83","author":"Peiper","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-086886","article-title":"Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study","volume":"392","author":"Cai","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0031","first-page":"1212","article-title":"Tirzepatide causes sexual dysfunction in women","volume":"9","year":"2024","journal-title":"Ann Pharmacol Pharm"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/11795476251347753","article-title":"Tirzepatide affect sexual function in women: case report","volume":"18","author":"Mohammed","year":"2025","journal-title":"Clin Med Insights Case Rep"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41443-024-00895-6","article-title":"Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study","volume":"37","author":"Able","year":"2025","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0034","first-page":"21","article-title":"(157) Prescribing Ozempic and Wegovy for weight loss is associated with an increased risk of erectile dysfunction and hypogonadism in non-diabetic males","author":"Liao","year":"2024","journal-title":"J Sex Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0035","doi-asserted-by":"crossref","first-page":"qdaf381","DOI":"10.1093\/jsxmed\/qdaf381","article-title":"Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review","volume":"23","author":"Deameh","year":"2026","journal-title":"J Sex Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0036","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41443-025-01061-2","article-title":"Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data","volume":"37","author":"Pourabhari Langroudi","year":"2025","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0037","doi-asserted-by":"crossref","first-page":"qfaf047","DOI":"10.1093\/sexmed\/qfaf047","article-title":"Anorgasmia following initiation of GLP-1 agonist","volume":"13","author":"Visvabharathy","year":"2025","journal-title":"Sex Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0038","article-title":"Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don\u2019t \u2018see\u2019 it","volume":"17","author":"Gelfand","year":"2026","journal-title":"Obes Pillars"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0039","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1111\/dom.70666","article-title":"Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials","volume":"28","author":"Eisa","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"10.1016\/j.clindermatol.2026.07.030_bib0040","first-page":"S277","article-title":"13. Older Adults: Standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0041","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S2213-8587(25)00092-0","article-title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","volume":"13","author":"Coskun","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0042","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0043","doi-asserted-by":"crossref","first-page":"9178","DOI":"10.1038\/s41598-025-91101-0","article-title":"Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes","volume":"15","author":"Suzuki","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0044","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0045","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1111\/dom.16541","article-title":"The effects of anti-obesity medications on bone metabolism: a critical appraisal","volume":"27","author":"Anastasilakis","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0046","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1210\/clinem\/dgag056","article-title":"GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes","volume":"111","author":"Kasher Meron","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0047","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/nu18040632","article-title":"A narrative review on GLP-1 receptor agonists for obesity in older women: maximizing weight loss while preserving lean mass","volume":"18","author":"Moscucci","year":"2026","journal-title":"Nutrients"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0048","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0049","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaophthalmol.2025.1455","article-title":"Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration","volume":"143","author":"Shor","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0050","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bjo-2025-328483","article-title":"Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk","volume":"110","author":"Lakhani","year":"2026","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0051","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.9917","article-title":"GLP-1 receptor agonists or SGLT2 inhibitors and nonarteritic anterior ischemic optic neuropathy","volume":"9","author":"Choi","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0052","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMc2600397","article-title":"Dulaglutide-associated choroidal lymphoid hyperplasia","volume":"394","author":"Francis","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0053","first-page":"S231","article-title":"12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0054","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.36849\/JDD.8605","article-title":"A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies","volume":"24","author":"Daniel","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0056","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00403-024-02969-3","article-title":"Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature","volume":"316","author":"Salazar","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0057","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdcr.2026.03.062","article-title":"Photodistributed exfoliative dermatitis associated with semaglutide: expanding the spectrum of glucagon-like peptide-1 receptor agonist-associated cutaneous reactions","volume":"72","author":"Kann","year":"2026","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0058","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study","volume":"92","author":"Burke","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0059","first-page":"1141","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"92","author":"Godfrey","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0060","doi-asserted-by":"crossref","unstructured":"Akiska Yea. Increased incidence and risk of hair loss with GLP-1 agonists: a real-world multicenter cohort study. EADV 2025. Paris, France.","DOI":"10.33590\/emjdermatol\/TYEW1122"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0061","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s13555-025-01537-5","article-title":"Benefit-risk assessment of GLP-1 receptor agonists: implications for dermatologists and plastic surgeons","volume":"15","author":"Cedirian","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0062","article-title":"A . Meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists","volume":"10","author":"Ogunremi","year":"2024","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0063","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaad.2025.02.009","article-title":"Glucagon-like peptide-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in nondiabetic obese women but not men: a retrospective cohort study","volume":"92","author":"Cho","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0064","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/ohn.1209","article-title":"Radiographic midfacial volume changes in patients on GLP-1 agonists","volume":"173","author":"Sharma","year":"2025","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0065","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/DSS.0000000000005180","article-title":"GLP-1-induced weight loss and the face: anatomical mechanisms and rationale for collagen-stimulating and volumizing aesthetic treatments","volume":"52","author":"Frank","year":"2026","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0066","doi-asserted-by":"crossref","first-page":"ojaf056","DOI":"10.1093\/asjof\/ojaf056","article-title":"Ozempic Face\" in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions","volume":"7","author":"Daneshgaran","year":"2025","journal-title":"Aesthet Surg J Open Forum"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2025.100298","article-title":"GLP-1 receptor agonist therapy and pregnancy: evolving and emerging evidence","volume":"25","author":"Varughese","year":"2025","journal-title":"Clin Med"},{"key":"10.1016\/j.clindermatol.2026.07.030_bib0068","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation","volume":"334","author":"Maya","year":"2025","journal-title":"JAMA"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:08:58Z","timestamp":1789186138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":67,"alternative-id":["S0738081X26002105"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.07.030","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating glucagon-like peptide-1 receptor agonists into dermatology practice: Safety and monitoring strategies","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}